Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts
Crofelemer is the only oral drug approved by the FDA's Center for Drug Evaluation and Research under Botanical Guidance
Click here to access replay of company's April 30, 2025 investor webcast
SAN FRANCISCO, CA / ACCESS Newswire / May 7, 2025 / Jaguar Health, Inc . (NASDAQ:JAGX) (Jaguar) today provided an overview of expected Q2 - Q4 2025 catalysts related to potential follow-on indications for crofelemer, the company's novel plant-based prescription drug approved by the U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER).
'As discussed during Jaguar's investor webcast last week, 2025 is a year of catalysts for crofelemer in both of our major development programs - our rare disease intestinal failure program and our cancer therapy-related diarrhea program,' said Lisa Conte, Jaguar's Founder and CEO. 'As a reminder, crofelemer is the only oral drug approved under the FDA's Botanical Guidance . It is not a biologic product. Click here to access the replay of our April 30, 2025 investor webcast.'
Rare Disease Intestinal Failure Program
Initial proof-of-concept (POC) results were issued last week for the ongoing investigator-initiated trial (IIT) of a novel liquid formulation of crofelemer in Abu Dhabi in the United Arab Emirates in pediatric patients with intestinal failure due to the rare orphan diseases microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF). The initial POC results, presented April 26, 2025 at the Annual ELITE PED-GI Congress , show crofelemer reduced the required total parenteral nutrition (TPN) and/or supplementary intravenous fluids, collectively referred to as parenteral support, in patients with intestinal failure due to MVID and SBS-IF by up to 27% and 12.5% respectively
Crofelemer also reduced stool volume output, frequency of watery stools, and increased urine output - indicating improved nutrient oral absorption
Based on these initial findings, crofelemer's novel antisecretory mechanism of action appears to have the potential to provide a novel therapeutic option to reduce TPN and associated complications, including liver, renal, and cognitive deficits, as well as infections from IV infusion, in this patient population
The observed TPN reduction is particularly compelling for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management and for which no approved drug treatments exist, or any potential approach to reduce TPN
This initial proof-of-concept data in MVID supports crofelemer's potential inclusion in the European Medicines Agency's (EMA) PRIME program for expediated and assisted regulatory approval in the EU as well as in the FDA's Breakthrough Therapy program for expedited regulatory approval in the US
Jaguar, through Jaguar family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics , is currently supporting three POC IITs, and conducting two placebo-controlled Phase 2 studies, for crofelemer for MVID and/or SBS-IF patients in the US, EU, and/or Middle East/North Africa regions
Additional POC results from IITs in MVID and/or SBS-IF are expected throughout 2025
Cancer Therapy-Related Diarrhea (CTD) Program
As announced, the FDA granted Napo a Type C Meeting in Q2 2025 to discuss the responder analysis results in the prespecified subgroup of patients with breast cancer in Napo's recently conducted Phase 3 OnTarget trial. Patients with breast cancer accounted for 183 of the 287 participants in this unprecedented prophylactic clinical trial of crofelemer for diarrhea in adults with solid tumors receiving targeted therapy with or without standard chemotherapy. While the initial top line results from the OnTarget study showed that this multicenter, double-blind, placebo-controlled pivotal trial did not meet its primary endpoint for the prespecified analysis of all tumor types, the subgroup analysis in adult breast cancer patients indicates that crofelemer achieved significant results in this subgroup. The company's goal for the meeting is to discuss the most efficient potential pathway to make crofelemer available to adult breast cancer patients for CTD.
The results in breast cancer patients were the subject of a poster presentation on December 11, 2024, at the San Antonio Breast Cancer Symposium , and additional significant results in adult breast cancer patients from the OnTarget study have been accepted for presentation as an oral rapid e-poster at the Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting in June 2025 in Seattle, Washington.
About Crofelemer
Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as 'dragon's blood,' of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health/
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky , X , Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute 'forward-looking statements.' These include statements regarding Jaguar's expectation that crofelemer's mechanism of action may have the potential to provide a novel therapeutic option to reduce TPN and associated complications, including liver, renal, and cognitive deficits, as well as infections from IV infusion, in pediatric MVID and SBS-IF patients, Jaguar's expectation that POC data in MVID may support crofelemer's potential inclusion in the EMA's PRIME program for expediated and assisted regulatory approval and in the FDA's Breakthrough Therapy program for expedited regulatory approval in the US, Jaguar's expectation that additional POC results from IITs will be available throughout 2025, Jaguar's expectation that Napo will meet with the FDA in Q2 2025 and discuss the most efficient potential pathway to make crofelemer available to adult breast cancer patients for CTD, and Jaguar's expectation that additional significant results in adult breast cancer patients from the OnTarget study will be presented at the 2025 MASCC Annual Meeting. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CONTACT:
[email protected]
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
an hour ago
- Forbes
20 Tips For Facilitating CEO Transitions
When a new CEO steps into the spotlight, internal communications teams play a pivotal role in shaping how the transition is perceived across the organization. The first impression employees form of their new leader often comes through the messages you craft, so timing, tone and transparency matter. A smooth transition is all about timely announcements, plenty of team interactions and creating space for trust to grow. To that end, 20 Forbes Communications Council members share practical steps you can take to guide your organization through this change in leadership. Internal comms pros can communicate, connect and collaborate. It's imperative to communicate clearly and promptly with employees. Engage with teams and allocate time for the CEO to meet with employees face-to-face. Jump into team meetings and articulate the objectives clearly. Activate the 100-day campaign where updates are scheduled every week for the first 100 days to communicate progress and strategy. - Alanood Aldhaher, American University of Sharjah Create a 90-day plan for socializing the new CEO within the company. This should include a listening tour and other opportunities for employees to provide feedback. Have the CEO reflect on what they are hearing. Employees will want to know how their lives will change under the new leader—giving them a voice throughout the transition will make them feel more included on any changes. - Patrick Holmes, Veteran Benefits Guide When a new CEO joins, there should be a series of proactive digital and physical touchpoints to introduce the leader personally, as well as communicate the leader's vision for the company. This will build trust and help align the organization under the new leadership. - Krystle Craycraft, NyTex Partners The first 90 days are key for visibility, listening and two-way communication. Plan events such as company town halls and other opportunities for employees to ask the new CEO questions about their approach and strategy for the business. Ensure the CEO is visible and responsive in internal communications as they ramp up. - Sheryl Seitz, C4 Ventures Emphasize an employee-first approach. I've seen too many employees find out about a new CEO from the front pages. Media coverage should be concurrent with internal announcements. There also must be clear messaging about the implications for the company, the various departments and employees. The internal communications team should continue to push management to prioritize relaying information. - Andrew Frank, KARV Forbes Communications Council is an invitation-only community for executives in successful public relations, media strategy, creative and advertising agencies. Do I qualify? A new CEO is a powerful opportunity to align employees with the vision of the company's leadership and to help each individual see how their role contributes to that success. But nature hates a vacuum, so move quickly to help the new CEO articulate and communicate that vision—also look for ways to help employees feel they know the new CEO as a human being and not just a title. - Elizabeth Baskin, Tribe, Inc. Connect the new CEO to the front line and middle management with every opportunity. When the CEO visits a company site for orientation, set up small meet-and-greet groups with informal agendas. Make it a listening tour more than anything else. This gives employees more direct access to the new chief executive while providing diverse insights from employees to the CEO. - Mark Dollins, North Star Communications Consulting One of the most overlooked but powerful steps internal comms can take is to narrate the transition in real time. Don't just announce the new CEO. Tell the story as it unfolds. Explain: Why did the change happen? What did the process look like? What can employees expect next? This builds transparency, reduces speculation and brings people along instead of leaving them behind. - Sara Payne, Inprela Communications When a new CEO joins, one thing that really helps is introducing him or her in a genuine, relatable way. Share who this person is, what they stand for and what they're excited to bring to the company. A short video, a Q&A or even a casual town hall goes a long way. It helps people feel included, reduces uncertainty and sets the tone for a smooth transition. - Luciana Cemerka, TP A new CEO's arrival is like launching a new brand, especially in turnarounds. Given that CEO hiring and performance oversight are core board duties, the board must be visible in the CEO rollout and ensure that marketing, communications, and HR lead with clarity. Starbucks got this right as Board Chair Mellody Hobson and CEO Brian Niccol modeled a high-trust launch that protected brand and stakeholder value. - Toby Wong, Toby Wong Consulting Shared context lowers stress levels. So, start by planning a live, all-hands AMA within the first few days of the new CEO's arrival, where staff submit questions anonymously and comms crafts candid replies linking the leader's vision to existing culture. Quick and empathetic transparency can turn uncertainty into collective momentum. - Jamie Elkaleh, Bitget Wallet Give the new CEO a voice before they ever speak. Share a playlist, a handwritten note or a photo of their hiking trip. Humanizing them through unconventional signals builds curiosity and trust faster than polished bios ever could. It makes the transition feel personal, not procedural. - Cade Collister, Metova There's already a lot of great advice out there on this topic. However, it is based on the assumption that internal comms pros are fully looped in. The most essential step to take during a new CEO transition is to make sure internal comms are engaged from the very early stages all the way through the transition period. Be a partner in the process and bring everyone along on the journey. - Barnaby Pung, Merit Network Schedule listening sessions for the new CEO within the first 30 days with as many key constituents as possible. Any time there is a change at that level, people get nervous. Change is inevitable since they didn't bring in the new person to just keep the status quo, but the agenda will be better absorbed if people feel like they got the opportunity to be heard. - Ted Hong, Solera Health Focus the messaging on why this CEO is the right fit for the future. Highlight their strengths, vision and what they bring to the table. When internal comms leads with excitement and clarity, not fear of change, it builds confidence, aligns teams faster and sets a positive tone for the transition. - Prateek Panda, Partner early with the CEO to craft a clear, authentic introduction plan, one that shares their vision, values and communication style. This builds trust, reduces uncertainty and sets the tone for transparency and alignment from day one. - Cody Gillund, Grounded Growth Studio Don't treat a new CEO's arrival like a top-secret operation! Internal comms pros should prioritize transparent and proactive communication from the moment the announcement is made. This upfront approach combats rumors and anxiety, fosters a sense of inclusion and allows employees to start aligning with the new leadership's vision from day one. - Patrick Ward, NanoGlobals Don't fall into the "100 days" trap. Great CEOs manage for the next decade, not the next few months. Think through the strategic positioning of everything you ask the CEO to say or do, and imagine how it will age over the years. - Bob Pearson, The Next Practices Group When a new CEO steps in, one of the best things internal communications can do is help the team understand that change is coming, and that's not bad. It starts with honest, human messaging that sets the tone: New leadership means fresh vision, and yes, our way of working might shift. But we don't lose our footing if we stay open and aligned. We grow together. - Rich Bornstein, Bornstein Media Employees are generally wary of uncertainty. Proactively sharing key aspects of a succession plan even before the CEO officially joins the team is an important step that internal comms pros can take to ensure a smooth transition. Addressing questions like "why now?" and "what does the transition mean for the company?" are just as important as who. The first two can be shared well in advance to reduce uncertainty. - Rekha Thomas, Path Forward Marketing
CBS News
2 hours ago
- CBS News
Breakthrough drug helps rare obesity condition, but other research uncertain amid cuts
Ali Foley Shenk still remembers the panic when her 10-year-old son, Dean, finished a 20-ounce box of raisins in the seconds the cupboard was left unlocked. They rushed to the emergency room, fearing a dangerous bowel impaction. The irony stung: When Dean was born, he was so weak and floppy he survived only with feeding tubes because he couldn't suck or swallow. He was diagnosed as a baby with Prader-Willi syndrome — a rare disorder sparked by a genetic abnormality. He continued to be disinterested in food for years. But doctors warned that as Dean grew, his hunger would eventually become so uncontrollable he could gain dangerous amounts of weight and even eat until his stomach ruptured. "It's crazy," said Foley Shenk, who lives in Richmond, Virginia. "All of a sudden, they flip." Prader-Willi syndrome affects up to 20,000 people in the U.S. The most striking symptom is its most life-threatening: an insatiable hunger known as hyperphagia that prompts caregivers to padlock cupboards and fridges, chain garbage cans, and install cameras. Until recently, the only treatment was growth hormone therapy to help patients stay leaner and grow taller, but it didn't address appetite. In March, the Food and Drug Administration approved Vykat XR, an extended-release version of the existing drug diazoxide choline, which eases the relentless hunger and may offer insights into the biology of extreme appetite and binge eating. This breakthrough for these patients comes as other drugs are revolutionizing how doctors treat obesity, which affects more than 40% of American adults. GLP-1 agonist medications Ozempic, Wegovy, and others also are delivering dramatic results for millions. But what's becoming clear is that obesity isn't one disease — it's many, said Jack Yanovski, a senior obesity researcher at the National Institutes of Health, who co-authored some of the Vykat XR studies. Researchers are learning that obesity's drivers can be environmental, familial, or genetic. "It only makes sense that it's complex to treat," Yanovski said. Obesity medicine is likely heading the way of treatments for high blood pressure or diabetes, with three to five effective options for different types of patients. For example, up to 15% of patients in the GLP-1 trials didn't respond to those drugs, and at least one study found the medications didn't significantly help Prader-Willi patients. Yet, researchers say, efforts to understand how to treat obesity's many causes and pathways are now in question as the Trump administration is dismantling the nation's infrastructure for medical discovery. While Health and Human Services Secretary Robert F. Kennedy Jr. promotes a "Make America Healthy Again" agenda centered on diet and lifestyle, federal funding for health research is being slashed, including some grants that support the study of obesity. University labs face cuts, FDA staffers are being laid off en masse, and rare disease researchers fear the ripple effects across all medical advances. Even with biotech partnerships — such as the work that led to Vykat XR — progress depends on NIH-funded labs and university researchers. "That whole thing is likely to get disrupted now," said Theresa Strong, research director for the Foundation for Prader-Willi Research. HHS spokesperson Andrew Nixon said in a statement that no NIH awards for Prader-Willi syndrome research have been cut. "We remain committed to supporting critical research into rare diseases and genetic conditions," he said. But Strong said that already some of the contacts at the FDA she'd spent nearly 15 years educating about the disorder have left the agency. She's heard that some research groups are considering moving their labs to Europe. Early progress in hunger and obesity research is transforming the life of Dean Shenk. During the trial for Vykat XR, his anxiety about food eased so much that his parents began leaving cupboards unlocked. Jennifer Miller, a pediatric endocrinologist at the University of Florida who co-led the Vykat XR trials, treats around 600 Prader-Willi patients, including Dean. She said the impact she's seen is life-changing. Since the drug trial started in 2018, some of her adult patients have begun living independently, getting into college, and starting jobs — milestones that once felt impossible. "It opens up their world in so many ways." Over 26 years in practice, she's also seen just how severely the disease hurts patients. One patient ate a four-pound bag of dehydrated potato flakes; another ingested all 10 frozen pizzas from a Costco pack; some ate pet food. Others have climbed out of windows, dived into dumpsters, even died after being hit by a car while running away from home in search of food. Low muscle tone, developmental delays, cognitive disabilities, and behavioral challenges are also common features of the disorder. Dean attends a special education program, his mother said. He also has narcolepsy and cataplexy — a sudden loss of muscle control triggered by strong emotions. His once-regular meltdowns and skin-picking, which led to deep, infected lesions, were tied to anxiety over his obsessive, almost painful urge to eat. In the trial, though, his hyperphagia was under control, according to Miller and Dean's mother. His lean muscle mass quadrupled, his body fat went down, and his bone mineral density increased. Even the skin-picking stopped, Foley Shenk said. Ali Foley Shenk (right) and her son Dean, at their home in Richmond, Virginia. Dean was born with Prader-Willi syndrome — a rare disorder that causes hyperphagia, a medical term for insatiable hunger. Since starting on a new medication as part of a clinical trial, his symptoms have improved, his mother says. Parker Michels-Boyce for KFF Health News Vykat XR is not a cure for the disease. Instead, it calms overactive neurons in the hypothalamus that release neuropeptide Y — one of the body's strongest hunger signals. "In most people, if you stop secreting NPY, hunger goes away," said Anish Bhatnagar, CEO of Soleno Therapeutics, which makes the medication, the company's first drug. "In Prader-Willi, that off switch doesn't exist. It's literally your brain telling you, 'You're starving,' as you eat." GLP-1 drugs, by contrast, mimic a gut hormone that helps people feel full by slowing digestion and signaling satiety to the brain. Vykat XR's possible side effects include high blood sugar, increased hair growth, and fluid retention or swelling, but those are trade-offs that many patients are willing to make to get some relief from the most devastating symptom of the condition. Still, the drug's average price of $466,200 a year is staggering even for rare-disease treatments. Soleno said in a statement it expects broad coverage from both private and public insurers and that the copayments will be "minimal." Until more insurers start reimbursing the cost, the company is providing the drug free of charge to trial participants. Soleno's stock soared 40% after the FDA nod and has held fairly steady since, with the company valued at nearly $4 billion as of early June. While Vykat XR may be limited in whom it can help with appetite control, obesity researchers are hoping the research behind it may help them decode the complexity of hunger and identify other treatment options. "Understanding how more targeted therapies work in rare genetic obesity helps us better understand the brain pathways behind appetite," said Jesse Richards, an internal medicine physician and the director of obesity medicine at the University of Oklahoma-Tulsa's School of Community Medicine. That future may already be taking shape. For Prader-Willi, two other notable phase 3 clinical trials are underway, led by Acadia Pharmaceuticals and Aardvark Therapeutics, each targeting different pathways. Meanwhile, hundreds of trials for general obesity are currently recruiting despite the uncertainties in U.S. medical research funding. That brings more hope to patients like Dean. Nearly six years after starting treatment, the now-16-year-old is a calmer, happier kid, his mom said. He's more social, has friends, and can focus better in school. With the impulse to overeat no longer dominating his every thought, he has space for other interests — Star Wars, American Ninja Warrior, and a healthy appreciation for avocados among them. "Before the drug, it just felt like a dead end. My child was miserable," Foley Shenk said. "Now, we have our son back." KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF — the independent source for health policy research, polling, and journalism.
Bloomberg
2 hours ago
- Bloomberg
Israel-Iran Conflict Begins to Disrupt Global Supply Chains
In their fourth day of fighting, with no end in sight, ripples from the Israeli-Iranian conflict are beginning to rock global supply chains. Some oil tanker owners and managers have paused offering their vessels for Middle Eastern routes as they assess the risks, fueling concerns over export flows from the region. The stability of shipping in and around the Middle East will be closely watched by markets in coming weeks. The region is home to about a third of the world's oil production, and major exporters such as Saudi Arabia and the United Arab Emirates have little room to divert exports should shipping be affected. Navigation signals from more than 900 vessels in the Strait of Hormuz and the Persian Gulf went awry over the weekend, creating confusion in the shipping chokepoint as the fighting intensified
